NICE launches scientific advice tie-up with Canadian agencyThe UK’s cost-effectiveness regulator NICE and the its counterpart in Canada have launched a new collaboration to offer Share XNICE launches scientific advice tie-up with Canadian agencyhttps://pharmaphorum.com/news/nice-launches-scientific-advice-tie-up-with-canadian-agency/
Novartis and Lilly CEOs back Trump plans to cut drug pricesCEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health Share XNovartis and Lilly CEOs back Trump plans to cut drug priceshttps://pharmaphorum.com/news/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices/
Vertex calls for changes to NICE as CF drug profits soarVertex has revealed financial figures that are likely to go down well with investors, but not patients in Share XVertex calls for changes to NICE as CF drug profits soarhttps://pharmaphorum.com/news/vertex-calls-for-changes-to-nice-as-cf-drug-profits-soar/
FDA accepts Merck & Co’s two new antibacterial drug applicationsThe FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Share XFDA accepts Merck & Co’s two new antibacterial drug applicationshttps://pharmaphorum.com/news/fda-accepts-merck-cos-two-new-antibacterial-drug-applications/
Campaigners urge NHS to ignore patents on Vertex’s CF drugThe fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called Share XCampaigners urge NHS to ignore patents on Vertex’s CF drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-ignore-patents-on-vertexs-cf-drug/
Roche seeks Kadcyla boost to fend off Herceptin biosimilarsAs biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer Share XRoche seeks Kadcyla boost to fend off Herceptin biosimilarshttps://pharmaphorum.com/news/roche-seeks-new-kadcyla-indication/
Europe’s CHMP recommends AZ’s Forxiga in type 1 diabetesThe European Medicines Agency’s CHMP regulatory committee has recommended AstraZeneca’s Forxiga to help adults with type 1 diabetes Share XEurope’s CHMP recommends AZ’s Forxiga in type 1 diabeteshttps://pharmaphorum.com/news/europes-chmp-recommends-azs-forxiga-in-type-1-diabetes/
Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
Novo accelerates launch plans for oral semaglutideNovo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in Share XNovo accelerates launch plans for oral semaglutidehttps://pharmaphorum.com/news/novo-accelerates-launch-plans-for-oral-semaglutide/
FDA finally approves Mylan’s Advair genericThe FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler, after years of Share XFDA finally approves Mylan’s Advair generichttps://pharmaphorum.com/news/fda-finally-approves-mylans-advair-generic/
NICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomaNICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did Share XNICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomahttps://pharmaphorum.com/news/nice-approves-novartis-car-t-therapy-for-diffuse-large-b-cell-lymphoma/
Brexit could hinder CAR-T reimbursement in EuropeBrexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, Share XBrexit could hinder CAR-T reimbursement in Europehttps://pharmaphorum.com/news/brexit-could-hinder-car-t-reimbursement-in-europe/
NICE aims to improve communications with UK life sciencesNICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness Share XNICE aims to improve communications with UK life scienceshttps://pharmaphorum.com/news/nice-aims-to-improve-communications-with-uk-life-sciences/
Cystic fibrosis patients lobby Vertex to drop drug pricesHealthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a Share XCystic fibrosis patients lobby Vertex to drop drug priceshttps://pharmaphorum.com/news/cystic-fibrosis-patients-lobby-vertex-to-drop-drug-prices/
CVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalUS pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to Share XCVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalhttps://pharmaphorum.com/news/cvs-covers-migraine-drugs-from-teva-and-lilly-excludes-amgens-rival/
FDA approves consumer colorectal cancer testThe FDA will allow consumer DNA testing company 23andMe to give customers reports on their risk of hereditary Share XFDA approves consumer colorectal cancer testhttps://pharmaphorum.com/news/fda-approves-consumer-colorectal-cancer-test/
Vertex’s CF drug gets label extension as pricing row continuesWhile UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received Share XVertex’s CF drug gets label extension as pricing row continueshttps://pharmaphorum.com/news/vertexs-cf-drug-gets-label-extension-as-pricing-row-continues/
Court backs NHS in hepatitis C procurement row with AbbVieA court has backed NHS England in a case where US pharma giant AbbVie had alleged that its Share XCourt backs NHS in hepatitis C procurement row with AbbViehttps://pharmaphorum.com/news/court-backs-nhs-in-hepatitis-c-procurement-row-with-abbvie/
